1. Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML.
- Author
-
Li, Zilin, Xi, Yiling, Tu, Linglan, Zhang, Xu, Huang, Yue, Nie, Huizong, Peng, Cheng, Chai, Haohuan, Zeng, Shenxin, Zheng, Xiaoliang, and Cheng, Liyan
- Subjects
- *
CHRONIC myeloid leukemia , *IMATINIB , *DEUBIQUITINATING enzymes , *DASATINIB , *NILOTINIB , *PROTEOLYSIS , *SMALL molecules - Abstract
Due to resistance and BCR-ABLT315I-mutated, CML remains a clinical challenge. It needs new potential therapeutic targets to overcome CML resistance related to BCR-ABL. Our research revealed that the deubiquitinating enzyme USP28 was highly expressed in BCR-ABL-dependent CML patients. Similarly, a high expression of USP28 was found in the K562 cell line, particularly in the imatinib-resistant strains. Notably, USP28 directly interacted with BCR-ABL. Furthermore, when BCR-ABL and its mutant BCR-ABLT315I were overexpressed in K562-IMR, they promoted the expression of IFITM3. However, when small molecule inhibitors targeting USP28 and small molecule degraders targeting BCR-ABL were combined, they significantly inhibited the expression of IFITM3. The experiments conducted on tumor-bearing animals revealed that co-treated mice showed a significant reduction in tumor size, effectively inhibiting the progression of CML tumors. In summary, USP28 promoted the proliferation and invasion of tumor cells in BCR-ABL-dependent CML by enhancing the expression of IFITM3. Moreover, imatinib resistance might be triggered by the activation of the USP28-BCR-ABL-IFITM3 pathway. Thus, the combined inhibition of USP28 and BCR-ABL could be a promising approach to overcome CML resistance dependent on BCR-ABL. [Display omitted] • DMP 11 is an innovatively synthesized protac compound targeting the degradation of the BCR-ABLfusion protein. • USP28 was correlated with the imatinib resistance in BCR-ABL-dependent CML. • Imatinib resistance may be triggered by the activation of the USP28-BCR-ABL-IFITM3 pathway. • Combined inhibition of USP28 and BCR-ABL may provide new potential therapeutic strategies to overcome CML resistance dependent on BCR-ABL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF